Jaffer A. Ajani

机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0001-9946-0629

发表论文 1735 篇 · 总被引 111688 次 · h-index 151

代表论文

• Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis (2025 · Gastric Cancer · 被引 3)
• YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases (2025 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 1)
• Efficacy and Safety of Anti-PD-(L)1 Treatments: A Systematic Review and Meta-analysis of Asian vs Non-Asian Patients With Esophageal Squamous Cell Carcinoma (2025 · Gastro Hep Advances · 被引 1)
• Pharmacologic Inhibition of SOX9-CDK4 by CYD-4-61 Impairs Gastric Adenocarcinoma Growth and Amplifies Anti-PD-1 Response (2026 · Cancer Letters)
• Abstract A078: TP101: First-in-class cancer stem cell–targeted small molecule combination therapy for epithelial malignancies (2026 · Clinical Cancer Research)
• Data from Association of Blood Levels of Forever Plastics with Lung Cancer Mortality among Ever Smokers in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cohort Study (2026)